IN2014MN01227A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01227A IN2014MN01227A IN1227MUN2014A IN2014MN01227A IN 2014MN01227 A IN2014MN01227 A IN 2014MN01227A IN 1227MUN2014 A IN1227MUN2014 A IN 1227MUN2014A IN 2014MN01227 A IN2014MN01227 A IN 2014MN01227A
- Authority
- IN
- India
- Prior art keywords
- patient
- methods
- relates
- heart
- heart damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92854107P | 2007-05-10 | 2007-05-10 | |
| PCT/US2008/006060 WO2008140814A1 (en) | 2007-05-10 | 2008-05-12 | Methods for detecting cardiac damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01227A true IN2014MN01227A (pt) | 2015-07-03 |
Family
ID=40002559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1227MUN2014 IN2014MN01227A (pt) | 2007-05-10 | 2008-05-12 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8628929B2 (pt) |
| EP (1) | EP2153228A4 (pt) |
| JP (5) | JP5749490B2 (pt) |
| CN (2) | CN104614510B (pt) |
| AU (1) | AU2008251822B2 (pt) |
| BR (1) | BRPI0810631A2 (pt) |
| CA (2) | CA2965208C (pt) |
| IN (1) | IN2014MN01227A (pt) |
| MX (2) | MX348082B (pt) |
| RU (1) | RU2498309C2 (pt) |
| WO (1) | WO2008140814A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628929B2 (en) | 2007-05-10 | 2014-01-14 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
| ES2609927T3 (es) | 2008-08-15 | 2017-04-25 | Acorda Therapeutics, Inc. | Composiciones y métodos para tratamientos durante periodos no agudos después de lesiones neurológicas del SNC |
| WO2010033249A2 (en) | 2008-09-22 | 2010-03-25 | Massachusetts Institute Of Technology | Compositions of and methods using ligand dimers |
| CN102232084B (zh) * | 2008-11-28 | 2014-05-28 | 上海泽生科技开发有限公司 | 纽兰格林及其用途 |
| US8835120B2 (en) * | 2009-12-02 | 2014-09-16 | Abbott Laboratories | Assay for cardiac troponin-T (cTnT) |
| US8652788B2 (en) * | 2009-12-02 | 2014-02-18 | Abbott Laboratories | Assay for diagnosis of cardiac myocyte damage |
| EP2555788B1 (en) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
| CN108387744A (zh) * | 2010-08-26 | 2018-08-10 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
| CA3103560C (en) | 2014-09-26 | 2023-01-17 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| RU2585391C1 (ru) * | 2014-12-19 | 2016-05-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Чеченский государственный университет | Способ иммунологического прогнозирования малых повреждений миокарда |
| WO2017053794A1 (en) * | 2015-09-25 | 2017-03-30 | Sawyer Douglas B | Methods for treating cardiac injury |
| RU2648529C1 (ru) * | 2016-12-27 | 2018-03-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ оценки эффективности лекарственной терапии у взрослых пациентов с острой сердечной недостаточностью после операций на открытом сердце, получающих лечение методом экстракорпоральной мембранной оксигенации |
| RU2709458C2 (ru) * | 2017-12-22 | 2019-12-18 | Марина Александровна Чичкова | Способ оптимизации ранней иммунологической диагностики осложнений чрескожного коронарного вмешательства у пациентов с ИБС |
| RU2722111C1 (ru) * | 2019-12-30 | 2020-05-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ ведения пациентов с хроническим лимфолейкозом в процессе полихимиотерапии по схеме fcr, направленный на предотвращение кардиотоксичности |
| RU2749552C1 (ru) * | 2020-08-03 | 2021-06-15 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ отбора пациентов с длительно персистирующей формой фибрилляции предсердий на проведение эффективного катетерного лечения |
| RU2760242C1 (ru) * | 2021-03-01 | 2021-11-23 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации | Способ оценки повреждения миокарда и риска развития осложнений после операций на сердце в условиях искусственного кровообращения |
| CN113238060B (zh) * | 2021-05-08 | 2022-10-11 | 迈克生物股份有限公司 | 用于预测或诊断心肌炎的试剂盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) * | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5324502A (en) * | 1992-04-02 | 1994-06-28 | Purdue Research Foundation | Radiopharmaceuticals for imaging the heart |
| US6092695A (en) | 1992-05-11 | 2000-07-25 | Cytologix Corporation | Interchangeable liquid dispensing cartridge pump |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| US6653249B1 (en) * | 2000-05-25 | 2003-11-25 | Penn Emblem Corporation | Emblem having calendered fabric layer |
| GB0029154D0 (en) * | 2000-11-30 | 2001-01-17 | Lee Helen | Signal enhancement with multiple labelled-antibodies |
| AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1267590C (zh) * | 2004-06-11 | 2006-08-02 | 清华大学 | 一种用于组织修复的生长因子缓释体系的制备方法 |
| CN1715926B (zh) * | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | 神经调节蛋白突变体的应用 |
| CA2614959A1 (en) | 2005-07-14 | 2007-01-25 | Myogen, Inc. | Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| US7776817B2 (en) | 2005-09-02 | 2010-08-17 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
| US8628929B2 (en) | 2007-05-10 | 2014-01-14 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
| DE102007061117A1 (de) | 2007-12-19 | 2009-06-25 | Robert Bosch Gmbh | Elektrische Kontaktierung |
| WO2012021818A2 (en) | 2010-08-13 | 2012-02-16 | Georgetown University | Ggf2 and methods of use |
-
2008
- 2008-05-12 US US12/451,397 patent/US8628929B2/en active Active
- 2008-05-12 CN CN201410827283.7A patent/CN104614510B/zh not_active Expired - Fee Related
- 2008-05-12 RU RU2009145695/15A patent/RU2498309C2/ru active
- 2008-05-12 CN CN200880021887.5A patent/CN101743474B/zh not_active Expired - Fee Related
- 2008-05-12 AU AU2008251822A patent/AU2008251822B2/en not_active Ceased
- 2008-05-12 MX MX2014013196A patent/MX348082B/es unknown
- 2008-05-12 WO PCT/US2008/006060 patent/WO2008140814A1/en active Application Filing
- 2008-05-12 CA CA2965208A patent/CA2965208C/en active Active
- 2008-05-12 MX MX2009012174A patent/MX2009012174A/es active IP Right Grant
- 2008-05-12 IN IN1227MUN2014 patent/IN2014MN01227A/en unknown
- 2008-05-12 BR BRPI0810631A patent/BRPI0810631A2/pt not_active Application Discontinuation
- 2008-05-12 JP JP2010507486A patent/JP5749490B2/ja not_active Expired - Fee Related
- 2008-05-12 EP EP08767674A patent/EP2153228A4/en not_active Withdrawn
- 2008-05-12 CA CA2686959A patent/CA2686959C/en active Active
-
2014
- 2014-01-13 US US14/153,695 patent/US9329171B2/en active Active
- 2014-03-31 JP JP2014071111A patent/JP5998171B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-25 US US15/053,284 patent/US9757429B2/en active Active
- 2016-08-29 JP JP2016166494A patent/JP6636402B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-10 US US15/674,053 patent/US10258667B2/en active Active
-
2018
- 2018-10-12 JP JP2018193389A patent/JP2019010123A/ja not_active Withdrawn
-
2019
- 2019-03-20 US US16/359,383 patent/US11071770B2/en active Active
-
2020
- 2020-07-17 JP JP2020122926A patent/JP6978553B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01227A (pt) | ||
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| EP2306814A4 (en) | METHOD FOR DIAGNOSING AND TREATING PATIENT TREATMENT OF A PATIENT | |
| NZ593474A (en) | Compositions and methods for treatment of celiac disease | |
| PL2349388T3 (pl) | Urządzenie i sposób do pozaustrojowej obróbki krwi | |
| IL209231A0 (en) | Scoring catheter for treating diseased heart valves | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| EP2150312A4 (en) | METHOD AND IMPLANTS FOR THE TREATMENT OF HEART FAILURES | |
| IL230911A0 (en) | A system for the treatment of heart tissue and its use | |
| WO2011092285A3 (en) | Means and methods for diagnosing heart failure in a subject | |
| MX336145B (es) | Metodo para el tratamiento de insuficiencia cardiaca cronica. | |
| EP2797633A4 (en) | BIOCOMPOSITE FOR THE REGENERATION OF FABRICS AND LOST ORGANS, KIT FOR PREPARING BIOCOMPOSITE, PROCESS FOR PREPARING BIOCOMPOSITE, AND METHOD FOR TREATING LESIONS | |
| MX2013002390A (es) | Tratamiento de infarto de miocardio usando antagonistas de tgf-beta. | |
| EA201190337A1 (ru) | Способ лечения | |
| EP2171450A4 (en) | ADAMTS4 AS BIOMARKER OF BLOOD AND THERAPEUTIC TARGET FOR CHRONIC RENAL FAILURE | |
| EP2263705A4 (en) | THERAPEUTIC AGENT AGAINST NERVE INJURY AND METHOD FOR TREATING NERVE INJURY | |
| EP2049198A4 (en) | METHOD AND DEVICE FOR TREATING CARDIAL TACHYARRHYTHMIES | |
| MX2007003790A (es) | Metodo de tratamiento. | |
| MX2010000938A (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. | |
| MX2012013374A (es) | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. | |
| GB201121914D0 (en) | Method for patient selection | |
| EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
| MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
| EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek |